Literature DB >> 11252695

Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude.

D M Bailey1, B Davies.   

Abstract

Acute mountain sickness; prophylactic benefits of Free-radical-mediated damage to the blood-brain barrier may be implicated in the pathophysiology of acute mountain sickness (AMS). To indirectly examine this, we conducted a randomized double-blind placebo-controlled trial to assess the potentially prophylactic benefits of enteral antioxidant vitamin supplementation during ascent to high altitude. Eighteen subjects aged 35 +/- 10 years old were randomly assigned double-blind to either an antioxidant (n = 9) or placebo group (n = 9). The antioxidant group ingested 4 capsules/day(-1) (2 after breakfast/2 after evening meal) that each contained 250 mg of L-ascorbic acid, 100 IU of dl-a-tocopherol acetate and 150 mg of alpha-lipoic acid. The placebo group ingested 4 capsules of identical external appearance, taste, and smell. Supplementation was enforced for 3 weeks at sea level and during a 10-day ascent to Mt. Everest base camp (approximately 5,180 m). Antioxidant supplementation resulted in a comparatively lower Lake Louise AMS score at high altitude relative to the placebo group (2.8 +/- 0.8 points versus 4.0 +/- 0.4 points, P = 0.036), higher resting arterial oxygen saturation (89 +/- 5% versus 85 +/- 5%, P = 0.042), and total caloric intake (13.2 +/- 0.6 MJ/day(-1) versus 10.1 +/- 0.7 MJ/day(-1), P = 0.001); the latter is attributable to a lower satiety rating following a standardized meal. These findings indicate that the exogenous provision of water and lipid-soluble antioxidant vitamins at the prescribed doses is an apparently safe and potentially effective intervention that can attenuate AMS and improve the physiological profile of mountaineers at high altitude.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252695     DOI: 10.1089/152702901750067882

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  32 in total

1.  Prevention and Treatment of High-altitude Illness in Travelers.

Authors:  David R. Murdoch
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Neuronal death during combined intermittent hypoxia/hypercapnia is due to mitochondrial dysfunction.

Authors:  Robert M Douglas; Julie Ryu; Amjad Kanaan; Maria Del Carmen Rivero; Laura L Dugan; Gabriel G Haddad; Sameh S Ali
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-31       Impact factor: 4.249

3.  Redox regulation of neurovascular function by acetazolamide: complementary insight into mechanisms underlying high-altitude acclimatisation.

Authors:  Damian M Bailey; Julien V Brugniaux; Sylvia Pietri; Marcel Culcasi; Erik R Swenson
Journal:  J Physiol       Date:  2012-08-01       Impact factor: 5.182

4.  THERAPEUTIC PERSPECTIVES ON THE COMBINATION OF ALPHA-LIPOIC ACID AND VITAMIN E.

Authors:  Oscar Gonzalez-Perez; Rocio E Gonzalez-Castaneda
Journal:  Nutr Res       Date:  2006-01-01       Impact factor: 3.315

5.  Protective effect of glutamine on intestinal injury and bacterial community in rats exposed to hypobaric hypoxia environment.

Authors:  Chun-Lan Xu; Rui Sun; Xiang-Jin Qiao; Cui-Cui Xu; Xiao-Ya Shang; Wei-Ning Niu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

6.  Changes in mitochondrial enzymatic activities of monocytes during prolonged hypobaric hypoxia and influence of antioxidants: A randomized controlled study.

Authors:  Tobias M Merz; Jacqueline Pichler Hefti; Urs Hefti; Andreas Huber; Stephan M Jakob; Jukka Takala; Siamak Djafarzadeh
Journal:  Redox Rep       Date:  2015-04-13       Impact factor: 4.412

Review 7.  High altitude and free radicals.

Authors:  Tibor Bakonyi; Zsolt Radak
Journal:  J Sports Sci Med       Date:  2004-06-01       Impact factor: 2.988

8.  Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).

Authors:  Jeffrey H Gertsch; Buddha Basnyat; E William Johnson; Janet Onopa; Peter S Holck
Journal:  BMJ       Date:  2004-03-11

9.  A potential role for reactive oxygen species and the HIF-1alpha-VEGF pathway in hypoxia-induced pulmonary vascular leak.

Authors:  David C Irwin; Joe M McCord; Eva Nozik-Grayck; Ginny Beckly; Ben Foreman; Tim Sullivan; Molly White; Joseph T Crossno; Damian Bailey; Sonia C Flores; Susan Majka; Dwight Klemm; Martha C Tissot van Patot
Journal:  Free Radic Biol Med       Date:  2009-04-07       Impact factor: 7.376

10.  Protein profiling reveals antioxidant and signaling activities of NAP (Davunetide) in rodent hippocampus exposed to hypobaric hypoxia.

Authors:  Niroj Kumar Sethy; Narendra Kumar Sharma; Mainak Das; Kalpana Bhargava
Journal:  J Mol Neurosci       Date:  2014-07-20       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.